Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$692.00K$692.00K−97.6% vs Q2 2025 Net Income-$31.78M-$31.78MN/M vs Q2 2025 EPS Diluted-$0.07-$0.07N/M vs Q2 2025 Operating Income-$26,540,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-3835.3%−3848.2 pt vs Q2 2025
Net margin-4591.8%−4603.0 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end